A systematic review and meta-analysis of randomized controlled trials investigating the effects of curcumin on blood lipid levels

Clinical Nutrition

Volumn 33, Issue 3, 2014, Pages 406-414

  Sahebkar, Amirhossein ^a  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cardiovascular disease; Cholesterol; Curcumin; Meta analysis; Polyphenol; Triglycerides

Indexed keywords

ALPHA TOCOPHEROL; ATORVASTATIN; CURCUMIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; PLANT MEDICINAL PRODUCT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHEMICAL PARAMETERS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; LOW DENSITY LIPOPROTEIN CHOLESTEROL BLOOD LEVEL; MALE; META ANALYSIS; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SYSTEMATIC REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CARDIOVASCULAR DISEASES; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR;

CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CURCUMIN; HUMANS; PHYTOCHEMICALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TRIGLYCERIDES;

EID: 84899624901     PISSN: 02615614     EISSN: 15321983     Source Type: Journal    
DOI: 10.1016/j.clnu.2013.09.012     Document Type: Article

References (60)

1. Roger V.L., Go A.S., Lloyd-Jones D.M., Benjamin E.J., Berry J.D., Borden W.B., et al. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation 2012, 125:e2-e220. American Heart Association Statistics Committee and Stroke Statistics Subcommittee.
2. American Heart Association International cardiovascular disease statistics 2004.
3. World Health Organization Atlas of heart disease and stroke 2004.
4. Musunuru K. Atherogenic dyslipidemia: cardiovascular risk and dietary intervention. Lipids 2010, 45:907-914.
5. Assmann G. Dyslipidaemia and global cardiovascular risk: clinical issues. Eur Heart J Suppl 2006, 8:F40-F46.
6. Gaw A. HDL-C and triglyceride levels: relationship to coronary heart disease and treatment with statins. Cardiovasc Drugs Ther 2003, 17:53-62.
7. Padala S., Thompson P.D. Statins as a possible cause of inflammatory and necrotizing myopathies. Atherosclerosis 2012, 222:15-21.
8. Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology 2005, 41:690-695.
9. Ye M.X., Li Y., Yin H., Zhang J. Curcumin: updated molecular mechanisms and intervention targets in human lung cancer. Int J Mol Sci 2012, 13:3959-3978.
10. Darvesha A.S., Aggarwal B.B., Bishayee A. Curcumin and liver cancer: a review. Curr Pharm Biotechnol 2012, 13:218-228.
11. Bachmeier B.E., Killian P., Pfeffer U., Nerlich A.G. Novel aspects for the application of curcumin in chemoprevention of various cancers. Front Biosci (Schol Ed) 2010, 2:697-717.
12. Shehzad A., Khan S., Shehzad O., Lee Y.S. Curcumin therapeutic promises and bioavailability in colorectal cancer. Drugs Today 2010, 46:523-532.
13. Teiten M.H., Gaascht F., Eifes S., Dicato M., Diederich M. Chemopreventive potential of curcumin in prostate cancer. Genes Nutr 2010, 5:61-74.
14. Zong H., Wang F., Fan Q.X., Wang L.X. Curcumin inhibits metastatic progression of breast cancer cell through suppression of urokinase-type plasminogen activator by NF-kappa B signaling pathways. Mol Biol Rep 2012, 39:4803-4808.
15. Odot J., Albert P., Carlier A., Tarpin M., Devy J., Madoulet C. Invitro and invivo anti-tumoral effect of curcumin against melanoma cells. Int J Cancer 2004, 111:381-387.
16. Hamaguchi T., Ono K., Yamada M. Curcumin and Alzheimer's disease. CNS Neurosci Ther 2010, 16:285-297.
17. Mythri R.B., Srinivas Bharath M.M. Curcumin: a potential neuroprotective agent in Parkinson's disease. Curr Pharm Des 2012, 18:91-99.
18. Taylor R.A., Leonard M.C. Curcumin for inflammatory bowel disease: a review of human studies. Altern Med Rev 2011, 16:152-156.
19. Chandran B., Goel A. Arandomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res 2012, 10.1002/ptr.4639.
20. Appendino G., Belcaro G., Cornelli U., Luzzi R., Togni S., Dugall M., et al. Potential role of curcumin phytosome (Meriva) in controlling the evolution of diabetic microangiopathy. A pilot study. Panminerva Med 2011, 53:S43-S49.
21. Wongcharoen W., Phrommintikul A. The protective role of curcumin in cardiovascular diseases. Int J Cardiol 2009, 133:145-151.
22. Wongcharoen W., Jai-Aue S., Phrommintikul A., Nawarawong W., Woraqidpoonpol S., Tepsuwan T., et al. Effects of curcuminoids on frequency of acute myocardial infarction after coronary artery bypass grafting. Am J Cardiol 2012, 110:40-44.
23. Venkatesan N. Curcumin attenuation of acute adriamycin myocardial toxicity in rats. Br J Pharmacol 1998, 124:425-427.
24. Yeh C.H., Chen T.P., Wu Y.C., Lin Y.M., Jing Lin P. Inhibition of NFkappaB activation with curcumin attenuates plasma inflammatory cytokines surge and cardiomyocytic apoptosis following cardiac ischemia/reperfusion. JSurg Res 2005, 125:109-116.
25. Morimoto T., Sunagawa Y., Kawamura T., Takaya T., Wada H., Nagasawa A., et al. The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. JClin Invest 2008, 118:868-878.
26. Li H.L., Liu C., de Couto G., Ouzounian M., Sun M., Wang A.B., et al. Curcumin prevents and reverses murine cardiac hypertrophy. JClin Invest 2008, 118:879-893.
27. Rungseesantivanon S., Thenchaisri N., Ruangvejvorachai P., Patumraj S. Curcumin supplementation could improve diabetes-induced endothelial dysfunction associated with decreased vascular superoxide production and PKC inhibition. BMC Complement Altern Med 2010, 10.
28. Ramaswami G., Chai H., Yao Q., Lin P.H., Lumsden A.B., Chen C. Curcumin blocks homocysteine-induced endothelial dysfunction in porcine coronary arteries. JVasc Surg 2004, 40:1216-1222.
29. Jang E.M., Choi M.S., Jung U.J., Kim M.J., Kim H.J., Jeon S.M., et al. Beneficial effects of curcumin on hyperlipidemia and insulin resistance in high-fat-fed hamsters. Metabolism 2008, 57:1576-1583.
30. Kapoor P., Ansari M.N., Bhandari U. Modulatory effect of curcumin on methionine-induced hyperlipidemia and hyperhomocysteinemia in albino rats. Indian J Exp Biol 2008, 46:534-540.
31. Manjunatha H., Srinivasan K. Hypolipidemic and antioxidant effects of dietary curcumin and capsaicin in induced hypercholesterolemic rats. Lipids 2007, 42:1133-1142.
32. Pari L., Murugan P. Antihyperlipidemic effect of curcumin and tetrahydrocurcumin in experimental type 2 diabetic rats. Ren Fail 2007, 29:881-889.
33. Majithiya J.B., Parmar A.N., Balaraman R. Effect of curcumin on triton WR 1339 induced hypercholesterolemia in mice. Indian J Pharmacol 2004, 36:382-383.
34. Shin S.K., Ha T.Y., McGregor R.A., Choi M.S. Long-term curcumin administration protects against atherosclerosis via hepatic regulation of lipoprotein cholesterol metabolism. Mol Nutr Food Res 2011, 55:1829-1840.
35. Ramírez-Boscá A., Soler A., Carrión M.A., Díaz-Alperi J., Bernd A., Quintanilla C., et al. An hydroalcoholic extract of Curcuma longa lowers the apo B/apo A ratio. Implications for atherogenesis prevention. Mech Ageing Dev 2000, 119:41-47.
36. Soni K.B., Kuttan R. Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. Indian J Physiol Pharmacol 1992, 36:273-275.
37. Pungcharoenkul K., Thongnopnua P. Effect of different curcuminoid supplement dosages on total invivo antioxidant capacity and cholesterol levels of healthy human subjects. Phytother Res 2011, 25:1721-1726.
38. Mohammadi A., Sahebkar A., Iranshahi M., Amini M., Khojasteh R., Ghayour-Mobarhan M., et al. Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial. Phytother Res 2012, 10.1002/ptr.4715.
39. Baum L., Cheung S.K., Mok V.C., Lam L.C., Leung V.P., Hui E., et al. Curcumin effects on blood lipid profile in a 6-month human study. Pharmacol Res 2007, 56:509-514.
40. Alwi I., Santoso T., Suyono S., Sutrisna B., Suyatna F.D., Kresno S.B., et al. The effect of curcumin on lipid level in patients with acute coronary syndrome. Acta Med Indones 2008, 40:201-210.
41. Usharani P., Mateen A.A., Naidu M.U., Raju Y.S., Chandra N. Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-week study. Drugs R D 2008, 9:243-250.
42. Cochrane handbook for systematic reviews of interventions version 5.0.2 2009, The Cochrane Collaboration. J.P.T. Higgins, S. Green (Eds.).
43. Shytle R.D., Bickford P.C., Rezai-zadeh K. Optimized turmeric extracts have potent anti-amyloidogenic effects. Curr Alzheimer Res 2009, 6:564-571.
44. Sharma R.A., Ireson C.R., Verschoyle R.D. Effects of dietary curcumin on glutathione S-transferase and malondialdehyde-DNA adducts in rat liver and colon mucosa: relationship with drug levels. Clin Cancer Res 2001, 7:1452-1458.
45. Anand P., Kunnumakkara A.B., Newman R.A., Aggarwal B.B. Bioavailability of curcumin: problems and promises. Mol Pharm 2007, 4:807-818.
46. Strimpakos A.S., Sharma R.A. Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal 2008, 10:511-545.
47. Quiles J.L., Mesa M.D., Ramírez-Tortosa C.L., Aguilera C.M., Battino M., Gil A., et al. Curcuma longa extract supplementation reduces oxidative stress and attenuates aortic fatty streak development in rabbits. Arterioscler Thromb Vasc Biol 2002, 22:1225-1231.
48. Xu Y., Ku B., Cui L., Li X., Barish P.A., Foster T.C., et al. Curcumin reverses impaired hippocampal neurogenesis and increases serotonin receptor 1A mRNA and brain-derived neurotrophic factor expression in chronically stressed rats. Brain Res 2007, 1162:9-18.
49. Mayanglambam A., Dangelmaier C.A., Thomas D., Damodar Reddy C., Daniel J.L., Kunapuli S.P. Curcumin inhibits GPVI-mediated platelet activation by interfering with the kinase activity of syk and the subsequent activation of PLC2. Platelets 2010, 21:211-220.
50. 2+ signaling. Biochem Pharmacol 1999, 58:1167-1172.
51. Srivastava R., Dikshit M., Srimal R.C., Dhawan B.N. Anti-thrombotic effect of curcumin. Thromb Res 1985, 40:413-417.
52. Chen H.W., Huang H.C. Effect of curcumin on cell cycle progression and apoptosis in vascular smooth muscle cells. Br J Pharmacol 1998, 124:1029-1040.
53. Jurenka J.S. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev 2009, 14:141-153.
54. Sahebkar A. Molecular mechanisms for curcumin benefits against ischemic injury. Fertil Steril 2010, 94:e75-e76. author reply e77.
55. Sahebkar A. Baicalin as a potentially promising drug for the management of sulfur mustard induced cutaneous complications: a review of molecular mechanisms. Cutan Ocul Toxicol 2012, 31:226-234.
56. Sahebkar A. Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. Phytother Res 2013, 10.1002/ptr.5045.
57. Sahebkar A. Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome?. Biofactors 2013, 39:197-208.
58. Sahebkar A., Mohammadi A., Atabati A., Rahiman S., Tavallaie S., Iranshahi M., et al. Curcuminoids modulate pro-oxidant-antioxidant balance but not the immune response to heat shock protein 27 and oxidized LDL in obese individuals. Phytother Res 2013, 10.1002/ptr.4952.
59. Sahebkar A., Morris D.R., Biros E., Golledge J. Association of single nucleotide polymorphisms in the gene encoding platelet endothelial cell adhesion molecule-1 with the risk of myocardial infarction: a systematic review and meta-analysis. Thromb Res 2013, 132:227-233.
60. Sahebkar A. Does PPARγ2 gene Pro12Ala polymorphism affect nonalcoholic fatty liver disease risk? Evidence from a meta-analysis. DNA Cell Biol 2013, 32:188-198.